Placenta Or Umbilical Cord Patents (Class 424/583)
-
Patent number: 8703207Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: August 2, 2013Date of Patent: April 22, 2014Assignee: Mimedx Group, Inc.Inventors: John Daniel, Randall Spencer, Robert Tofe, John Russo
-
Publication number: 20140088339Abstract: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.Type: ApplicationFiled: March 1, 2013Publication date: March 27, 2014Applicant: Francis Law GroupInventor: Robert Matheny
-
Patent number: 8642092Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: April 11, 2013Date of Patent: February 4, 2014Assignee: Mimedx Group, Inc.Inventors: John Daniel, Randall Spencer, John Russo, Robert Tofe
-
Patent number: 8623421Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.Type: GrantFiled: July 26, 2013Date of Patent: January 7, 2014Assignee: MiMedx Group, Inc.Inventor: John Daniel
-
Patent number: 8617535Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.Type: GrantFiled: November 3, 2006Date of Patent: December 31, 2013Assignee: Anthrogenesis CorporationInventor: Robert J. Hariri
-
Publication number: 20130344163Abstract: Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.Type: ApplicationFiled: March 13, 2013Publication date: December 26, 2013Inventors: Scheffer TSENG, Ek Kia TAN, Amy TSENG
-
Patent number: 8597687Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.Type: GrantFiled: August 7, 2012Date of Patent: December 3, 2013Assignee: Mimedx Group, Inc.Inventor: John Daniel
-
Publication number: 20130309317Abstract: The present invention provides a food supplement, which comprises: a placental extract and an oil; which would promote the proliferation of CD34+ stem cells and increase the telomerase activity to achieve rejuvenation and anti-aging.Type: ApplicationFiled: September 4, 2012Publication date: November 21, 2013Applicant: GWO XI STEM CELL APPLIED TECHNOLOGY CO. LTD.Inventors: HORNG-JYH HARN, SHINN-ZONG LIN, PO-CHENG LIN, HSIN-I WANG, PI-CHUN HUANG
-
Publication number: 20130287741Abstract: Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.Type: ApplicationFiled: December 12, 2012Publication date: October 31, 2013Inventor: AlloSource
-
Publication number: 20130280344Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: ApplicationFiled: March 13, 2013Publication date: October 24, 2013Applicant: TISSUETECH, INC.Inventor: TissueTech, Inc.
-
Patent number: 8562973Abstract: Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or disorder.Type: GrantFiled: April 6, 2011Date of Patent: October 22, 2013Assignee: Anthrogenesis CorporationInventors: James W. Edinger, Steven Alan Fischkoff, Aleksandar Francki, Vladimir Jankovic, Bitao Liang, Philippe Martin, Cynthia Ray, Xiaokui Zhang
-
Patent number: 8562972Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.Type: GrantFiled: October 23, 2007Date of Patent: October 22, 2013Assignee: Anthrogenesis CorporationInventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
-
Publication number: 20130251670Abstract: Described are methods of treating macular edema, as well as other complications of ocular inflammation, through the administration of various stem cell populations and conditioned media thereof. In one embodiment a patient suffering from macular edema is administered an intramuscular dose of media conditioned by placental mesenchymal stem cells at a sufficient concentration and frequency to elicit a reduction in ocular inflammation. Other embodiments of the invention teach intra-ocular, intravenous, sublingual, and oral means of delivery conditioned media from various stem cell populations that has been optimized for anti-inflammatory, regenerative, and immune modulatory properties.Type: ApplicationFiled: September 13, 2012Publication date: September 26, 2013Applicant: Aidan Products, IncInventors: Neil H. Riordan, Jorge Paz Rodriguez
-
Publication number: 20130243882Abstract: The present invention provides a method for treating a skin wound in a subject, which comprises administering the skin wound with a composition comprising umbilical mesenchymal stem cells. More particularly, the composition is used for improving wound healing.Type: ApplicationFiled: March 25, 2011Publication date: September 19, 2013Inventors: Yu-Show Fu, Yang-Hsin Shih
-
Publication number: 20130216505Abstract: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.Type: ApplicationFiled: December 31, 2012Publication date: August 22, 2013Inventor: Amit Patel
-
Publication number: 20130195993Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: TISSUETECH, INC.Inventor: TISSUETECH, INC.
-
Publication number: 20130195994Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: TISSUETECH, INC.Inventor: TISSUETECH, INC.
-
Publication number: 20130195992Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: ApplicationFiled: March 12, 2013Publication date: August 1, 2013Applicant: TISSUETECH, INC.Inventor: TissueTech, Inc.
-
Publication number: 20130156847Abstract: Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.Type: ApplicationFiled: November 29, 2012Publication date: June 20, 2013Applicant: MEDISTEM INC.Inventor: Medistem Inc.
-
Publication number: 20130156863Abstract: Disclosed herein, in certain instances, are tissue grafts derived from chorion or amnio-chorion. Further disclosed herein, in certain instances, are use for tissue grafts derived from chorion or amnio-chorion.Type: ApplicationFiled: June 30, 2011Publication date: June 20, 2013Applicant: TISSUETECH, INC.Inventors: Scheffer Tseng, Ek Kia Tan, Lorraine Siok May Chua
-
Patent number: 8460650Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.Type: GrantFiled: February 12, 2008Date of Patent: June 11, 2013Assignee: Anthrogenesis CorporationInventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
-
Patent number: 8460714Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: April 3, 2012Date of Patent: June 11, 2013Assignee: TissueTech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Patent number: 8460715Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.Type: GrantFiled: August 7, 2012Date of Patent: June 11, 2013Assignee: MiMedx Group, Inc.Inventor: John Daniel
-
Patent number: 8460716Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.Type: GrantFiled: August 7, 2012Date of Patent: June 11, 2013Assignee: MiMedx Group, Inc.Inventor: John Daniel
-
Patent number: 8455009Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: April 23, 2012Date of Patent: June 4, 2013Assignee: TissueTech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Publication number: 20130129836Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: ApplicationFiled: January 15, 2013Publication date: May 23, 2013Applicant: MIMEDX GROUP, INC.Inventor: MiMedx Group, Inc.
-
Patent number: 8440235Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: April 23, 2012Date of Patent: May 14, 2013Assignee: TissueTech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Patent number: 8435788Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.Type: GrantFiled: June 24, 2010Date of Patent: May 7, 2013Assignee: Anthrogenesis CorporationInventor: Robert J. Hariri
-
Publication number: 20130095061Abstract: Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions.Type: ApplicationFiled: November 29, 2012Publication date: April 18, 2013Inventors: Michael Cohen, Jacob Cohen
-
Patent number: 8420126Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: April 23, 2012Date of Patent: April 16, 2013Assignee: Tissue Tech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Patent number: 8409626Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: August 7, 2012Date of Patent: April 2, 2013Assignee: MiMedx Group, Inc.Inventors: John Daniel, Robert Tofe, Randall Spencer, John Russo
-
Patent number: 8372437Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.Type: GrantFiled: August 17, 2007Date of Patent: February 12, 2013Assignee: Mimedx Group, Inc.Inventor: John Daniel
-
Patent number: 8372438Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: August 7, 2012Date of Patent: February 12, 2013Assignee: Mimedx Group, Inc.Inventors: John Daniel, Robert Tofe, Randall Spencer, John Russo
-
Patent number: 8372439Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: August 7, 2012Date of Patent: February 12, 2013Assignee: Mimedx Group, Inc.Inventors: John Daniel, Robert Tofe, Randall Spencer, John Russo
-
Patent number: 8357403Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: September 8, 2008Date of Patent: January 22, 2013Assignee: Mimedx Group, Inc.Inventors: John Daniel, Robert Tofe, Randall Spencer, John Russo
-
Publication number: 20120328690Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: ApplicationFiled: April 23, 2012Publication date: December 27, 2012Applicant: Bio-Tissue, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Publication number: 20120321575Abstract: The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent.Type: ApplicationFiled: August 8, 2012Publication date: December 20, 2012Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Graca Raposo, Cédric Delevoye, Danièle Tenza, Ilse Hurbain
-
Publication number: 20120315259Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.Type: ApplicationFiled: February 1, 2011Publication date: December 13, 2012Inventor: Hyman Friedlander
-
Patent number: 8323701Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.Type: GrantFiled: April 23, 2009Date of Patent: December 4, 2012Assignee: Mimedx Group, Inc.Inventors: John Daniel, Robert Tofe, Randall Spencer, John Russo
-
Publication number: 20120276215Abstract: Disclosed are therapeutic compositions useful for treatment of degenerative, autoimmune, inflammatory, and neurological conditions. In one embodiment, clinical conditions are treated by administration of a standardized composition of stem cell, progenitor cell, or cellular supernatant. The invention provides doses of conditioned media that mediate therapeutic effects at concentrations that would not be expected to produce biological effects.Type: ApplicationFiled: April 26, 2012Publication date: November 1, 2012Inventors: Neil H. Riordan, Jorge Paz Rodriguez
-
Publication number: 20120269880Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: ApplicationFiled: April 3, 2012Publication date: October 25, 2012Applicant: Tissue Tech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Publication number: 20120258083Abstract: The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia.Type: ApplicationFiled: June 19, 2012Publication date: October 11, 2012Inventor: Michael P. Murphy
-
Publication number: 20120251526Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: ApplicationFiled: May 8, 2012Publication date: October 4, 2012Inventors: Charlotte A Smith, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 8278102Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.Type: GrantFiled: December 21, 2006Date of Patent: October 2, 2012Inventors: Jane Ennis, Rahul Sarugaser, John E. Davies
-
Publication number: 20120195969Abstract: Disclosed are methods and compositions for treatment of acne or acneform conditions, particularly but not limited to, acne vulgaris with products generated from culture of stem or progenitor cells. Specifically, compositions of matter are disclosed which are useful for the treatment of acne and acne associated disease states, in particular acne vulgaris, by topical administration of products derived from stem cells or progenitor cells.Type: ApplicationFiled: September 29, 2011Publication date: August 2, 2012Applicant: AIDAN RESEARCH AND CONSULTING, LLCInventors: Neil H. Riordan, Tierney M. Riordan
-
Publication number: 20120156230Abstract: Provided herein are methods of treatment of individuals having an injury to the central nervous system, such as a spinal cord injury or a traumatic brain injury, using placental stem cells and placental multipotent stem cells described herein, and populations of such placental cells.Type: ApplicationFiled: December 15, 2011Publication date: June 21, 2012Inventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Bitao Liang
-
Publication number: 20120141595Abstract: Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.Type: ApplicationFiled: August 25, 2010Publication date: June 7, 2012Applicant: TissueTech, Inc.Inventors: Scheffer Tseng, Ek Kia Tan, Amy Tseng
-
Patent number: 8187639Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: September 27, 2006Date of Patent: May 29, 2012Assignee: Tissue Tech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Patent number: 8182840Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: September 27, 2006Date of Patent: May 22, 2012Assignee: Tissue Tech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li
-
Patent number: 8182841Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.Type: GrantFiled: September 27, 2006Date of Patent: May 22, 2012Assignee: Tissue Tech, Inc.Inventors: Scheffer Tseng, Hua He, Wei Li